EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

Phase 2

Terminated

Conditions: Differentiated Thyroid Gland Carcinoma
Thyroid Gland Follicular Carcinoma
Thyroid Gland Papillary Carcinoma

Interventions: Drug: Lenvatinib

First Posted Date: 2018-04-23

Last Posted Date: 2022-11-10

Lead Sponsor: Emory University

Target Recruit Count: 4

Registration Number: NCT03506048

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Trikafta in Cystic Fibrosis Patients

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Trikafta

First Posted Date: 2018-04-23

Last Posted Date: 2024-07-09

Lead Sponsor: Emory University

Target Recruit Count: 42

Registration Number: NCT03506061

Locations: 🇺🇸
University of Alabama Cystic Fibrosis Research Center, Birmingham, Alabama, United States
🇺🇸
Emory Children's Center, Atlanta, Georgia, United States

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia
Follicular Lymphoma
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Interventions: Biological: Inactivated Influenza Vaccine

First Posted Date: 2018-04-18

Last Posted Date: 2024-02-23

Lead Sponsor: Emory University

Target Recruit Count: 200

Registration Number: NCT03501576

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Meditation for Pain

Not Applicable

Completed

Conditions: Chronic Pain

Interventions: Behavioral: Headspace app

First Posted Date: 2018-04-12

Last Posted Date: 2020-04-13

Lead Sponsor: Emory University

Target Recruit Count: 115

Registration Number: NCT03495726

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy

Phase 1

Completed

Conditions: Stage II Lung Cancer
Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
Stage I Non-Small Cell Lung Cancer AJCC v7
Stage IA Non-Small Cell Lung Carcinoma AJCC v7
Stage IB Non-Small Cell Lung Carcinoma AJCC v7
Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
Stage I Lung Cancer
Stage II Non-Small Cell Lung Cancer AJCC v7

Interventions: Drug: Fludeoxyglucose F-18
Procedure: Positron Emission Tomography (PET)
Radiation: Stereotactic Body Radiation Therapy (SBRT)

First Posted Date: 2018-04-11

Last Posted Date: 2023-10-18

Lead Sponsor: Emory University

Target Recruit Count: 19

Registration Number: NCT03493789

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Smartstep Smartphone PAD

Not Applicable

Recruiting

Conditions: Peripheral Arterial Disease

Interventions: Behavioral: Standard exercise therapy
Behavioral: Smartphone-enabled structured exercise therapy (SE-SET)

First Posted Date: 2018-03-27

Last Posted Date: 2023-09-06

Lead Sponsor: Emory University

Target Recruit Count: 50

Registration Number: NCT03479255

Locations: 🇺🇸
Grady Health System (non-CRN), Atlanta, Georgia, United States

Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Single dose of Genvoya® and a single 800 mg dose of Darunavir®

First Posted Date: 2018-03-21

Last Posted Date: 2020-08-28

Lead Sponsor: Emory University

Target Recruit Count: 35

Registration Number: NCT03472963

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States

Effect of Ketorolac on Post Adenotonsillectomy Pain

Phase 4

Completed

Conditions: Obstructive Sleep Apnea

Interventions: Drug: Ketorolac
Drug: Standard of Care

First Posted Date: 2018-03-16

Last Posted Date: 2024-03-20

Lead Sponsor: Emory University

Target Recruit Count: 63

Registration Number: NCT03467750

Locations: 🇺🇸
Childrens Healthcare of Atlanta, Egleston, Atlanta, Georgia, United States

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Head and Neck Carcinoma
Paranasal Sinus Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Hypopharyngeal Squamous Cell Carcinoma
Recurrent Laryngeal Squamous Cell Carcinoma
Recurrent Oral Cavity Squamous Cell Carcinoma
Recurrent Oropharyngeal Squamous Cell Carcinoma
Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7